» Articles » PMID: 38257396

Antitumor Mechanism and Therapeutic Potential of Cordycepin Derivatives

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2024 Jan 23
PMID 38257396
Authors
Affiliations
Soon will be listed here.
Abstract

Cordycepin has good antitumor activity, but its clinical application is limited due to the easy deamination of N6 in structure. In this study, a large lipolysis group was introduced at the cordycepin N6 to improve the problem, cordycepin derivatives (-) were synthesized, and biological evaluation of compounds was studied. In this study, the vitro antitumor activity of the compounds against MCF7 cells, HepG2 cells and SGC-7901 cells was evaluated by MTT assay. In the results, compound showed the most obvious inhibitory effect on MCF7 cells with an IC value of 27.57 ± 0.52 μM, which was much lower than cordycepin. Compound showed high selectivity between MCF7 and normal MCF-10A cells. Further biological evaluation showed that compound promoted apoptosis and blocked the cell cycle in the G0/G1 phase. Then, Western Blot was used to detect related apoptotic proteins. It was found that Compound could down-regulate the expression of Bcl-2 protein and up-regulate the expression of p53, Bax, Caspase-3 and Caspase-9 proteins. The mitochondrial membrane potential decreased continuously and the positive expression rate decreased. It was speculated that compound induced the apoptosis of MCF7 cells through the mitochondrial pathway.

References
1.
Yue K, Ye M, Zhou Z, Sun W, Lin X . The genus Cordyceps: a chemical and pharmacological review. J Pharm Pharmacol. 2013; 65(4):474-93. DOI: 10.1111/j.2042-7158.2012.01601.x. View

2.
Han F, Dou M, Wang Y, Xu C, Li Y, Ding X . Cordycepin protects renal ischemia/reperfusion injury through regulating inflammation, apoptosis, and oxidative stress. Acta Biochim Biophys Sin (Shanghai). 2020; 52(2):125-132. DOI: 10.1093/abbs/gmz145. View

3.
Lee C, Huang K, Shaw J, Chen J, Kuo W, Shen G . Trends in the Immunomodulatory Effects of : Total Extracts, Polysaccharides and Cordycepin. Front Pharmacol. 2020; 11:575704. PMC: 7735063. DOI: 10.3389/fphar.2020.575704. View

4.
Dong J, Li Y, Xiao H, Luo D, Zhang S, Zhu C . Cordycepin sensitizes breast cancer cells toward irradiation through elevating ROS production involving Nrf2. Toxicol Appl Pharmacol. 2018; 364:12-21. DOI: 10.1016/j.taap.2018.12.006. View

5.
Liao X, Gao Y, Zhao H, Zhou M, Chen D, Tao L . Cordycepin Reverses Cisplatin Resistance in Non-small Cell Lung Cancer by Activating AMPK and Inhibiting AKT Signaling Pathway. Front Cell Dev Biol. 2021; 8:609285. PMC: 7843937. DOI: 10.3389/fcell.2020.609285. View